ABOUT THE CHOROIDAL MELANOMA RESULTS:
Patients Entered: Any patient with choroidal melanoma who returns for follow-up and therefore presents to The New York Eye Cancer Center waiting room qualifies for these results.
Average Vision: The average visual acuity results of all patients with choroidal melanoma seen at the NYECC who qualify for entry into the results page.
Most Common Vision: The most common visual acuity measured at each patient’s last visit to the NYECC is averaged in with all the other patients.
Local Tumor Destruction: Average percentage of choroidal melanomas destroyed by Dr. Finger’s plaque radiation therapy among patients seen at the NYECC. Each patient’s local eye cancer control is updated at each visit. Patients who have had their eye removed as initial treatment are not included. All patients choroidal melanoma results are averaged in with the other patients results. There are no specific patient identifiers and so we are HIPPA compliant.
Initial Eye Removal: Percentage of patients whose eyes (with choroidal melanoma) had to be removed as first and thus primary treatment versus eye and vision sparing treatment (like radiation).
Metastases: The percentage of patients who have returned to the NYECC who are living with systemic spread of their choroidal melanoma. These results do not include all patients who have developed metastatic disease after either radiation or eye removal treatment. For a better understanding of that statistic, ask Dr. Finger.
Average follow up (in years): This statistic averages the length of time since treatment for all patients treated for choroidal melanoma and seen at the NYECC for follow up.
ALSO NOTE:
- Data includes for results for only patients treated for choroidal melanoma by Dr. Finger.
- Patients data is kept confidential, anonymous and thus HIPAA-compliant in that this data is averaged in with all the other patient’s outcomes; no individual patient can be identified.
- Starting from December 2017, every patient’s results with choroidal melanoma was anonymously recorded at each visit to The New York Eye Cancer Center. Selection included: only patients who returned for scheduled follow up examinations/treatments (no patient who did not return for more than 12 months.
- Patients who had to have their eye removed as primary treatment were not included in our visual acuity outcomes. Patients who had their eye removed after radiation therapy had their vision was averaged into our results as “0.”
- Visual acuity outcomes of hand motions, light perception and no light perception were averaged in as a value of “0.”
